Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Sells $62,912.85 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the sale, the general counsel now owns 160,437 shares in the company, valued at approximately $729,988.35. This represents a 7.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Benjamin Landry also recently made the following trade(s):

• On Monday, January 6th, Benjamin Landry sold 2,500 shares of Health Catalyst stock. The stock was sold at an average price of $7.52, for a total transaction of $18,800.00.

Health Catalyst Trading Up 6.2 %

Shares of HCAT stock opened at $4.43 on Thursday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average price of $5.56 and a two-hundred day moving average price of $7.10. Health Catalyst, Inc. has a 12-month low of $3.76 and a 12-month high of $9.24. The firm has a market cap of $311.03 million, a P/E ratio of -3.28 and a beta of 1.41.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Citigroup decreased their price target on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Stephens decreased their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Piper Sandler decreased their price target on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 11th. Wells Fargo & Company decreased their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a report on Tuesday, January 21st. Finally, Canaccord Genuity Group decreased their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.27.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new position in shares of Health Catalyst in the fourth quarter worth about $29,000. Group One Trading LLC increased its holdings in shares of Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after buying an additional 2,260 shares during the period. Quest Partners LLC purchased a new position in shares of Health Catalyst in the third quarter worth about $34,000. Aquatic Capital Management LLC purchased a new position in shares of Health Catalyst in the fourth quarter worth about $63,000. Finally, Stoneridge Investment Partners LLC purchased a new position in shares of Health Catalyst in the fourth quarter worth about $77,000. 85.00% of the stock is owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.